Itoreg-R Capsule SR is a combination pharmaceutical formulation containing Rabeprazole 20 mg and Itopride 150 mg, designed for the management of gastrointestinal disorders. Rabeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and providing symptomatic relief in acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, facilitating gastric emptying and improving symptoms of functional dyspepsia, including bloating, nausea, and early satiety. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing efficacy and patient compliance by reducing dosing frequency. Itoreg-R Capsule SR is indicated for patients presenting with combined symptoms of acid hypersecretion and impaired gastric motility. The combination therapy addresses both acid suppression and motility enhancement, offering comprehensive symptomatic relief. Caution is advised in patients with hypersensitivity to either component, and it should be used under medical supervision, particularly in those with hepatic or renal impairment. Adverse effects may include headache, diarrhea, or abdominal discomfort, and monitoring is recommended during prolonged therapy.